Loading
A phase 3 trial of M701 run by Wuhan YZY Biopharma Co., Ltd., active.
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody is a phase 3 interventional study registered as NCT06432296 by Wuhan YZY Biopharma Co., Ltd., with 312 participants enrolled, started 2024-03-25. Conditions listed: Malignant Ascites. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/